Indian biotech firm, Biocon Ltd, and Abu Dhabi-based pharma manufacturer, Neopharma, have set up NeoBiocon, a joint venture to be based at the Dubai Biotechnology and Research Park (DuBiotech).
The aim of NeoBiocon is to offer affordable biopharmaceutical products in areas such as oncology, diabetes, auto-immune disorders, cardiology and anti-obesity.
“NeoBiocon is a pioneering joint venture with Neopharma… Our long term vision is to ensure that the region is self-sufficient in terms of biopharmaceutical products,” said Kiran Mazumdar-Shaw, managing director, Biocon.
The company, established in 1978, developed the recombinant human insulin, INSUGEN, and India’s first indigenously produced monoclonal antibody, BIOMAb-EGFR.
Follow us on
